Argent BioPharma Company Description

Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide.

The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer.

It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment.

The company has collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care.

The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited.

Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Argent BioPharma Limited

Country	Australia
Founded	2014
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	Roby Zomer

Contact Details

Address: 295 Rokeby Road Subiaco, 6008 Australia
Phone	61 8 6555 2950
Website	argentbiopharma.com

Stock Details

Ticker Symbol	RGT
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU000000MXC6
SIC Code	2834

Key Executives

Name	Position
Sasha Friedman	Deputy Chief Executive Officer
Roby Reuven Zomer	Co-Founder, Chief Executive Officer and Chairman
Igor Bluvstein	Chief Financial Officer
Shachar Shimony	Group General Counsel
Amir Polak	Chief Pharmaceutical Development Officer
Sabina Suljakovic	Chief Quality and Commercial Officer
Dr. Nadya Lisovoder	Chief Medical Officer
Yair Tal	Chief Information Security Officer
Rowan Harland	Company Secretary
Ana Arhar Oblak	Group Financial Controller